ESMO Events 2024

Meetings se abre en una nueva pestaña/ventana | ESMO se abre en una nueva pestaña/ventana

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Immuno-Oncology 2024 se abre en una nueva pestaña/ventana

The event brings together oncologists, researchers, healthcare professionals, and industry representatives from Asia and around the world.

This international event provides an advanced educational programme and showcases recent scientific developments in this promising and fast-evolving field.

From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, this event will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study se abre en una nueva pestaña/ventana F. Lordick ∙ M.E. Mauer ∙ G. Stocker∙ C.A. Cella ∙ I. Ben-Aharon ∙ G. Piessen ∙ L. Wyrwicz ∙ G. Al-Haidari∙ T. Fleitas-Kanonnikoff ∙ V. Boige ∙ R. Lordick Obermannová ∙ U.M. Martens ∙ C. Gomez-Martin ∙ P. Thuss-Patience ∙ V. Arrazubi ∙ A. Avallone ∙ K.K. Shiu ∙ P. Artru ∙ B. Brenner ∙ C. Buges Sanchez ∙ I. Chau ∙ S. Lorenzen ∙ S. Daum ∙ M. Sinn∙ B. Merelli ∙ N.C.T. van Grieken ∙ M. Nilsson ∙ M. Collienne ∙ A. Giraut ∙ E. Smyt

• Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial se abre en una nueva pestaña/ventana P. Harter ∙ C. Marth ∙ M.-A. Mouret-Reynier ∙ C. Cropet ∙ D. Lorusso ∙ E.M. Guerra-Alía ∙ T. Matsumoto ∙ I. Vergote ∙ N. Colombo ∙ J. Mäenpää ∙ C. Lebreton ∙ N. de Gregorio ∙ A.M. Mosconi ∙ M.J. Rubio-Pérez ∙ H. Bourgeois ∙ P.A. Fasching ∙ S.C. Cecere ∙ A.-C. Hardy-Bessard ∙ D. Denschlag ∙ S. de Percin ∙ L. Hanker ∙ L. Favier ∙ D. Bauerschla,† ∙ C. Desauw ∙ P. Hillemanns ∙ R. Largillier ∙ J. Sehouli ∙J. Grenier∙ E. Pujade-Lauraine ∙ I. Ray-Coquard on behalf of the PAOLA-1/ENGOT-ov25 investigators‡

ESMO Open

• Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer se abre en una nueva pestaña/ventana G. Nader-Marta ∙ A.G. Waks∙ S.M. Tolaney ∙ E.L. Mayer

• Recursive partitioning analysis model for de novo metastatic nasopharyngeal carcinoma treated with locoregional radiotherapy following chemoimmunotherapy se abre en una nueva pestaña/ventana D. Wen† ∙ L. Gu† ∙ H. Long† ∙ S. Liu† ∙ M. Luo ∙ R. Li ∙ R. Liu ∙ J. Lin ∙ J. Jin ∙ L. Xiong∙ L. Tang ∙ H. Mai ∙ L. Liu ∙ Y. Liang ∙ Q. Chen ∙ S. Guo

Immuno-Oncology and Technology

• Integrated noninvasive diagnostics for prediction of survival in immunotherapy se abre en una nueva pestaña/ventana M. Yeghaian∙ Z. Bodalal ∙ T.M. Tareco Bucho ∙ I. Kurilova ∙ C.U. Blank ∙ E.F. Smit ∙ M.S. van der Heijden ∙ T.D.L. Nguyen-Kim ∙ D. van den Broek ∙ R.G.H. Beets-Tan ∙ S. Trebeschi

• An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy se abre en una nueva pestaña/ventana E. Michielon† ∙ L.A. King† ∙ T. Waaijman ∙ M. Veth ∙ S.W. Spiekstra ∙ H.J. van der Vliet ∙ S. Gibbs ∙ T.D. de Gruij

The Breast

• Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes se abre en una nueva pestaña/ventana Foteinos-Ioannis Dimitrakopoulosa, ∙ Anna Goussiac,d ∙ Georgia-Angeliki Kolioue ∙ Katerina Dadoulif ∙ Anna Batistatouc ∙ Helen P. Koureag ∙ Mattheos Bobosh, ∙ Petroula Arapantoni-Dadiotij ∙ Olympia Tzaidak ∙ Triantafyllia Koletsal ∙ Sofia Chrisafih ∙ Maria Sotiropouloum ∙ Alexandra Papoudou-Baic ∙ Irene Nicolaoun ∙ Antonia Charchantio ∙ Davide Maurip ∙ Gerasimos Aravantinosq ∙ Ioannis Binasr ∙ Eleni Ress ∙ Amanda Psyrrit ∙ Dimitrios Pectasidesu ∙ Dimitrios Bafaloukosv ∙ Anna Koumarianouw ∙ Iliada Bompolakix ∙ Georgios Rigakosy ∙ Charisios Karanikiotisz ∙ Angelos Koutrasa ∙ Flora Zagouriaa ∙ Helen Gogasab ∙ George Fountzilash

Cancer Treatment Reviews

• Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma se abre en una nueva pestaña/ventana Miaoying Caia ∙ Yifu Wanga, ∙ Huangrong Maa ∙ Li Yangb ∙ Zhiyuan Xub

• Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: New frontiers and unveiled opportunities for cancer immunotherapy se abre en una nueva pestaña/ventana Simone Ielpoa, ∙ Francesca Barberinia, Farnaz Dabbagh Moghaddamb ∙ Silvia Pescec, ∙ Chiara Cencionie ∙ Francesco Spallottaf, ∙ Adele De Ninnob ∙ Luca Businarob ∙ Emanuela Marcenaroc, ∙ Roberto Beia ∙ Loredana Cifaldia ∙ Giovanni Barillaria, ∙ Ombretta Melaiua

Lung Cancer

• CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients’ prognosis treated with chemoimmunotherapy se abre en una nueva pestaña/ventana Zhexin Baia ∙ Xu Chenga ∙ Tianyu Maa ∙ Gege Lia ∙ Xiaojue Wanga ∙ Ziyu Wangb ∙ Ling Yib ∙ Zhidong Liua

• Neoadjuvant Therapy in early-stage non-small cell lung cancer: A real-world analysis se abre en una nueva pestaña/ventana Leyla Aya, ∙ Daniel Steinerc ∙ Hannah Fabikana ∙ Oliver Illinia, ∙ Dagmar Krenbekd ∙ Thomas Klikovitse ∙ Michal Beneje ∙ Klaus Kirchbachera, ∙ Stefan Watzkae, ∙ Arschang Valipoura, ∙ Maximilian Hochmaira

Clinical Lymphoma, Myeloma and Leukemia

• The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma se abre en una nueva pestaña/ventana Ritu Chakrabarti ∙ David Siegel ∙ Noa Biran

• Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives se abre en una nueva pestaña/ventana Johannes M. Waldschmidt ∙ Leo Rasche ∙ K. Martin Kortüm ∙ Hermann Einsele

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.